SENS

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Diabetes, Health, Medical Devices, Research, NYSE, Telephone, Real, Investment, CGM, Marketing, Eastern Time Zone, Conference, Doctor of Philosophy, SENS, Pharmaceutical industry, Security (finance), Video game

U.S. revenue was $3.9 million in the third quarter of 2023 compared to $1.9 million in the prior year period, and revenue outside the U.S. was $2.2 million in the third quarter of 2023 compared to $2.7 million in the prior year period.

Key Points: 
  • U.S. revenue was $3.9 million in the third quarter of 2023 compared to $1.9 million in the prior year period, and revenue outside the U.S. was $2.2 million in the third quarter of 2023 compared to $2.7 million in the prior year period.
  • Third quarter 2023 gross profit of $1.2 million increased from $0.8 million in gross profit for the third quarter of 2022.
  • Third quarter 2023 sales and marketing and general and administrative expenses increased by $0.1 million year-over-year, to $7.4 million.
  • Third quarter 2023 research and development expenses increased by $1.8 million year-over-year, to $12.8 million.

Sensirion Holding AG announces changes to the Executive Board and Board of Directors

Retrieved on: 
Thursday, December 14, 2023
SENS, University of St. Gallen, Engineering, Doctor of Philosophy, Head, Science, Packaging and labeling, SIX Swiss Exchange, ABB, Supervisory board, University, Annual general meeting, Business administration, ETH Zurich, Management, Investment

Sensirion Holding AG (SIX Swiss Exchange: SENS), headquartered in Stäfa, Switzerland, a leading manufacturer of digital microsensors and systems, announces changes to its Executive Board and Board of Directors.

Key Points: 
  • Sensirion Holding AG (SIX Swiss Exchange: SENS), headquartered in Stäfa, Switzerland, a leading manufacturer of digital microsensors and systems, announces changes to its Executive Board and Board of Directors.
  • Rahel Meuwly has been appointed as the new VP Human Resources and member of the Executive Board as of 1 November 2023.
  • The Board of Directors will propose the election of Henri Mrejen at the upcoming Annual General Meeting.
  • Henri Mrejen is also the Chairman of Supervisory Board of Tecinvest Holding AG, the global leader for laser beam deflection systems, based in Germany.

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Diabetes, Medical Devices, Health, Health Technology, CGM, SENS, Interest, Conference, NYSE, Medical device

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.
  • Management is scheduled to present on Tuesday, November 14, 2023 from 4:45pm to 5:15pm ET.
  • Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time

Retrieved on: 
Monday, October 30, 2023
Diabetes, Medical Devices, Health, Clinical Trials, Health Technology, CGM, Toys "R" Us Canada, SENS, NYSE American, Eastern Time Zone, Webcast, International, Publication, Medical device, Broadcasting

Management will hold a conference call to review the Company’s third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.

Key Points: 
  • Management will hold a conference call to review the Company’s third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day.
  • The conference call will be concurrently webcast.
  • The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference.
  • To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 1409312, approximately ten to five minutes prior to start time.

Dr. Christopher Fox and N.P. Sarah Sato Collaborate with Castle Connolly Private Health Partners to Create The Alpine Center CCPHP Concierge Medicine Program

Retrieved on: 
Monday, October 16, 2023
Endocrinology, SENS, Metabolism, Patient satisfaction, SUPERIOR, Diabetes, Trust, Patient, Concierge medicine, Exercise, Sleep, Physician, Medical device, Nursing

SUPERIOR, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Castle Connolly Private Health Partners, LLC (CCPHP), a leader in concierge medicine, has collaborated with Dr. Christopher Fox and N.P.

Key Points: 
  • SUPERIOR, Colo., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Castle Connolly Private Health Partners, LLC (CCPHP), a leader in concierge medicine, has collaborated with Dr. Christopher Fox and N.P.
  • Sarah Sato to establish The Alpine Center CCPHP, a concierge (membership model) medicine program.
  • This collaboration will enable the providers to offer their Patient-Members amenities and enhancements and a more proactive and personalized approach to healthcare.
  • “The concierge model offers a rewarding experience for physicians and patients,” said Dean McElwain, CCPHP CEO and co-founder.

Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Retrieved on: 
Monday, October 9, 2023
Nursing, Medical Devices, Health, Diabetes, Biometrics, Managed Care, NYSE, Real, Advertising, SENS, TSE, Safety, Himawari (satellites), Webcast, CGM, Comparison of multi-paradigm programming languages, Physician, Attention, Life, Patient, Practitioner, Pharmaceutical industry

‘The CGM for Real Life’ campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes.

Key Points: 
  • ‘The CGM for Real Life’ campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes.
  • For the 37 million people living with diabetes in the U.S.ii, CGM has become an indispensable tool in managing the condition.
  • Eversense E3 is the longest lasting CGM available, with 6-month sensor wear duration and two sensor insertion and removal procedures per year.
  • Thankfully, with Eversense it doesn’t.”
    ‘The CGM for Real Life’ campaign is a coordinated awareness effort delivering information about Eversense E3 directly to U.S. consumers.

Ascensia Diabetes Care and Senseonics Announce 'The CGM for Real Life' Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

Retrieved on: 
Monday, October 9, 2023
ADA, NYSE, SENS, Advertising, Statistics, TSE, Safety, Real Life, Diabetes, Himawari (satellites), Webcast, CGM, American Diabetes Association, Comparison of multi-paradigm programming languages, Physician, Attention, Patient, Practitioner, Pharmaceutical industry

PARSIPPANY, N.J., Oct. 9, 2023 /PRNewswire/ -- Ascensia Diabetes Care, a global diabetes care company, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, have launched a new U.S. advertising and marketing campaign for Eversense® E3 CGM System. 'The CGM for Real Life' campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes. A sample of the new advertising assets can be found here.

Key Points: 
  • 'The CGM for Real Life' campaign is designed to significantly drive awareness of Eversense E3 as a unique CGM option that is ideally suited to supporting the everyday lives of people with diabetes.
  • Eversense E3 is the longest lasting CGM available, with 6-month sensor wear duration and two sensor insertion and removal procedures per year.
  • The campaign demonstrates how Eversense E3 provides a differentiated CGM option, with unparalleled flexibility and long-term use that allows it to seamlessly integrate into real life.
  • 'The CGM for Real Life' campaign is a coordinated awareness effort delivering information about Eversense E3 directly to U.S. consumers.

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Retrieved on: 
Tuesday, September 26, 2023
Research, Apps, Applications, Technology, Medical Devices, Diabetes, Clinical Trials, Health Technology, Biotechnology, Health, Science, CGM, Trial of the century, GlySens ICGM, FDA, NYSE, Patient, SENS, Safety, Medical device

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient.
  • “We are pleased that all patients have completed the testing for the adult arm of the ENHANCE clinical study.
  • Demonstration of safe and accurate performance of Eversense® for 365 days in this study would further validate its ability to facilitate more effective and longer-term management of diabetes.
  • Data gathered in this study was also used to support the FDA submission for the integrated continuous glucose monitoring, iCGM, designation earlier in 2023.

SENS to Supply Revolutionary SuperTorque 8Z Genset Starting System for Wyoming Hyperscale's Caterpillar C175-20 Gensets

Retrieved on: 
Friday, September 15, 2023
SENS, Nickel–zinc battery, Compact, GHG, UL, Hyperscale computing, Computation, Caterpillar, Longevity, TCO, Lithium, Electric battery

LONGMONT, Colo., Sept. 15, 2023 /PRNewswire/ -- Stored Energy Systems LLC (SENS) announced that it will be supplying Wyoming Hyperscale the revolutionary SuperTorque 8Z across the Wyoming HyperScale datacenter and campus.

Key Points: 
  • LONGMONT, Colo., Sept. 15, 2023 /PRNewswire/ -- Stored Energy Systems LLC (SENS) announced that it will be supplying Wyoming Hyperscale the revolutionary SuperTorque 8Z across the Wyoming HyperScale datacenter and campus.
  • The SuperTorque 8Z is the power generation industry's first fully integrated starting battery and charger system, powered by ZincFive® long-life, safe, reliable, high-power Nickel-Zinc (NiZn) technology.
  • This state-of-the-art system addresses the most pressing issue with emergency generators: the sudden and unexpected failure of starting batteries.
  • "Our collaboration with SENS is a testament to our trust and confidence in the SuperTorque 8Z system."

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

Retrieved on: 
Thursday, September 14, 2023
Finance, Health, Diabetes, Medical Devices, Health Technology, Professional Services, Technology, Apps, Applications, CGM, Interest, NYSE, SENS, Pharmaceutical industry, Cryptocurrency, Medical device

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.

Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually.
  • Management is scheduled to present on Thursday, September 21, 2023 from 11:30 a.m. to 11:55 a.m.
  • ET.
  • Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com .